Severe hyperglycemia during renally adjusted gatifloxacin therapy

Annals of Pharmacotherapy

Volumn 39, Issue 7-8, 2005, Pages 1349-1352

  Blommel, Amy L ^a,b   Lutes, Ronald A ^a  

^a Monongahela Valley Hospital   (United States)

^b Monongahela Valley Hospital ^*  (United States)

Author keywords

Gatifloxacin; Hyperglycemia

Indexed keywords

GATIFLOXACIN; GLUCOSE; INSULIN;

AGED; ARTICLE; BRONCHITIS; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH PRACTITIONER; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFECTIVE AGENTS; BLOOD GLUCOSE; BRONCHITIS; FEMALE; FLUOROQUINOLONES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAVENOUS; INSULIN; KIDNEY DISEASES; RENAL DIALYSIS;

EID: 21744460399     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E679     Document Type: Article

References (17)

1. Package insert. Tequin (gatifloxacin). Princeton, NJ: Bristol-Meyers Squibb, revised October 2003.
2. Package insert. Cipro (ciprofloxacin). West Haven, CT: Bayer, revised April 2004.
3. Package insert. Levaquin (levofloxacin). Raritan, NJ: Ortho-McNeil, revised July 2004.
4. Package insert. Avelox (moxifloxacin). West Haven, CT: Bayer, revised November 2000.
5. Ambrose PG, Bhavnani SM, Cirincione BB, Piedmonte M, Grasela TH. Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003;52:435-40. DOI 10.1093/jac/dkg370
6. Donaldson AR, Vandiver JR, Finch CK. Possible gatifloxacin-induced hyperglycemia. Ann Pharmacother 2004;38:602-5. DOI 10.1345/aph.1D360
7. Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003;16:455-7.
8. Arce FC, Bhasin RS, Pasmantier R. Severe hyperglycemia during gatifloxacin therapy in patients without diabetes. Endocrine Pract 2004;10:40-4.
9. Happe MR, Mulhall BP, Maydonovitch CL, Holtzmuller KC. Gatifloxacin-induced hyperglycemia. Ann Intern Med 2004;141:968-9.
10. Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G, Birkhofer MJ, et al. A dose-escalation study for the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men. Pharmacotherapy 2000;20:495-585.
11. Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin Infect Dis 2000;31(suppl 2):S51-8.
12. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978-82.
13. Package insert. Protonix (pantoprazole). Philadelphia: Wyeth Laboratories, revised 2003.
14. Lakhdar AA, Farish E, Dunn FG, Hillis WS. Amiodarone therapy and glucose tolerance-a prospective trial. Eur J Clin Pharmacol 1988;34: 651-2.
15. Package insert. Furosemide. North Chicago, IL: Abbott Laboratories, revised May 1999.
16. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
17. Tailor SAN, Simor AE, Cornish W, Phillips E, Knowles S, Rachlis A. Analysis of spontaneous reports of hypoglycemia and hyperglycemia associated with marketed systemic fluroquinolones made to the Canadian adverse drug reaction monitoring program. Can J Hosp Pharm 2004;57:12-7.